A high level of DUXAP9 is positively associated with lymph node metastasis, poor pathological differentiation, advanced clinical stage, worse overall survival, and worse disease‐specific survival in OSCC patients. This evidence concerns the gene DUXAP9 and metastatic malignant neoplasm in the lymph nodes.